Complement Activation in End Stage Renal Failure during Haemodialysis
Research type
Research Study
Full title
Investigating complement activation in patients with end stage renal failure during haemodialysis.
IRAS ID
315138
Contact name
Sandip Mitra
Contact email
Sponsor organisation
Manchester University NHS Foundation Turst
Duration of Study in the UK
0 years, 11 months, 31 days
Research summary
Patients with kidney failure require regular essential renal replacement therapy in the form of dialysis. This results in exposure to the dialysis circuit on average three times a week. Evidence shows this repeated exposure to these materials results in increased inflammation within the blood. Over the decades, dialysis has been improved to minimise this reaction however recent evidence shows that despite this, in some patients, ongoing inflammation occurs with each session.
Persistent inflammation has been linked to an increased risk of heart disease, risk of stroke and damage to blood vessels. The purpose of this study is to identify in which group of patients this ongoing inflammation occurs. This valuable information will allow us to trial treatment designed to reduce or even stop this from happening.REC name
Yorkshire & The Humber - South Yorkshire Research Ethics Committee
REC reference
22/YH/0162
Date of REC Opinion
26 Sep 2022
REC opinion
Further Information Favourable Opinion